One stock that might be an intriguing choice for investors right now is BioTime, Inc. BTX. This is because this security in the Medical-Biomedical/Genetics space is seeing solid earnings estimate ...
BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ...
BioTime, Inc.Peter Garcia, 510-521-3390, ext 367Chief Financial OfficerorJudith Segall, 510-521-3390, ext 301orLifeMap Sciences, Inc.Kenneth Elsner, 781-826-7719COO BioTime, Inc. (NYSE MKT: BTX) and ...
BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced ™Portal Offering Additional ™ Human Progenitor Cells Including Those for Diabetes Research BioTime, Inc. (NYSE MKT: BTX) and ...
ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem® hydrogel technology platform. The first of these new ...
Resource is expected to help researchers select the most suitable progenitor cell lines. Regenerative medicines firm BioTime has teamed up with XenneX to establish LifeMap Sciences, an intiiative that ...
This East Bay molecular diagnostics company shunned the traditional IPO route to go public on the market's first trading day of 2016. Its stock jumped on its first day of trading on Monday. An East ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) announced today that its Senior Vice President and Chief Operating Officer, Robert W. Peabody, will reassume the additional role of ...
Company will merge Xennex into LifeMap Sciences subsidiary. BioTime is to acquire Xennex to take over the latters’ global marketing rights to the GeneCards® and PanDaTox® databases. BioTime says it ...
On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results